RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

被引：0
|
作者：
Petrylak, D. P. [1 ]
Sternberg, C. N. [2 ]
Drakaki, A. [3 ]
de Wit, R. [4 ]
Nishiyama, H. [5 ]
Necchi, A. [6 ]
Castellano, D. [7 ]
Bamias, A. [8 ]
Chi, K. N. [9 ]
van der Heijden, M. S. [10 ]
Matsubara, N. [11 ]
Hussain, S. [12 ]
Flechon, A. [13 ]
Alekseev, B. Y. [14 ]
Yu, E. Y. [15 ]
Walgren, R. A. [16 ]
Russo, F. [17 ]
Zimmermann, A. H. [16 ]
Bell-Mcguinn, K. M. [16 ]
Powles, T. B. [18 ]
机构：
[1] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA
[2] Azienda Osped S Camillo Forlanini, Med Oncol, Rome, Italy
[3] Univ Calif Los Angeles, Med Ctr, Med, Los Angeles, CA 90024 USA
[4] Erasmus MC, Med Oncol, Daniel den Hoed Canc Ctr, Rotterdam, Netherlands
[5] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan
[6] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[7] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
[8] Univ Athens, Clin Therapeut, Sotiria Gen Chest Dis Hosp, Athens, Greece
[9] British Columbia Canc Agcy, Med Oncol, Vancouver, BC, Canada
[10] Nederlands Kanker Inst Antoni van Leeuwenhoek NKI, Med Oncol, Amsterdam, Netherlands
[11] Natl Canc Ctr Hosp East, Oncol, Kashiwa, Chiba, Japan
[12] Plymouth Univ, Oncol, Plymouth, Devon, England
[13] Ctr Leon Berard, Med Oncol, Lyon, France
[14] Herzen Canc Res Inst, Oncol, Moscow, Russia
[15] Univ Washington, Med Oncol, Seattle, WA 98195 USA
[16] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[17] Eli Lilly & Co, Oncol, Florence, SC USA
[18] St Bartholomews Hosp, Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
865PD
引用
收藏
页数：2
相关论文
共 50 条
  • [1] RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma
    Petrylak, D. P.
    Chi, K. N.
    Drakaki, A.
    Sternberg, C. N.
    de Wit, R.
    Nishiyama, H.
    Yu, E. Y.
    Castellano, D.
    Hussain, S.
    Percent, I. J.
    Flechon, A.
    Bamias, A.
    Van der Heijden, M. S.
    Matsubara, N.
    Alekseev, B.
    Walgren, R. A.
    Hamid, O.
    Zimmermann, A. H.
    Bell-Mcguinn, K. M.
    Powles, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts).
    De Wit, Ronald
    Powles, Thomas
    Castellano, Daniel E.
    Necchi, Andrea
    Lee, Jae-Lyun
    Van der Heijden, Michiel Simon
    Matsubara, Nobuaki
    Bamias, Aristotelis
    Flechon, Aude
    Sternberg, Cora N.
    Drakaki, Alexandra
    Yu, Evan Y.
    Hamid, Oday
    Zimmermann, Annamaria H.
    Gao, Ling
    Long, Amanda
    Walgren, Richard A.
    Bell-McGuinn, Katherine M.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC)
    Matsubara, Nobuaki
    Petrylak, Daniel Peter
    Nishiyama, Hiroyuki
    Su, Wen-Pin
    Lee, Jae-Lyun
    Li, Jian-Ri
    Walgren, Richard A.
    Hamid, Oday
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Gao, Ling
    Homma, Gosuke
    Yana, Ikuo
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC).
    Necchi, Andrea
    Nishiyama, Hiroyuki
    Matsubara, Nobuaki
    Lee, Jae-Lyun
    Petrylak, Daniel Peter
    De Wit, Ronald
    Drakaki, Alexandra
    Liepa, Astra M.
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy
    De Wit, Ronald
    Powles, Thomas
    Castellano, Daniel E.
    Necchi, Andrea
    Lee, Jae-Lyun
    Van der Heijden, Michiel Simon
    Matsubara, Nobuaki
    Bamias, Aristotelis
    Flechon, Aude
    Sternberg, Cora N.
    Drakaki, Alexandra
    Yu, Evan Y.
    Hamid, Oday
    Zimmermann, Annamaria
    Gao, Ling
    Long, Amanda
    Walgren, Richard A.
    Bell-McGuinn, Katherine M.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
    Petrylak, Daniel P.
    de Wit, Ronald
    Chi, Kim N.
    Drakaki, Alexandra
    Sternberg, Cora N.
    Nishiyama, Hiroyuki
    Castellano, Daniel
    Hussain, Syed A.
    Flechon, Aude
    Bamias, Aristotelis
    Yu, Evan Y.
    van der Heijden, Michiel S.
    Matsubara, Nobuaki
    Alekseev, Boris
    Necchi, Andrea
    Geczi, Lajos
    Ou, Yen-Chuan
    Coskun, Hasan Senol
    Su, Wen-Pin
    Bedke, Jens
    Gakis, Georgios
    Percent, Ivor J.
    Lee, Jae-Lyun
    Tucci, Marcello
    Semenov, Andrey
    Laestadius, Fredrik
    Peer, Avivit
    Tortora, Giampaolo
    Safina, Sufia
    Garcia del Muro, Xavier
    Rodriguez-Vida, Alejo
    Cicin, Irfan
    Harputluoglu, Hakan
    Tagawa, Scott T.
    Vaishampayan, Ulka
    Aragon-Ching, Jeanny B.
    Hamid, Oday
    Liepa, Astra M.
    Wijayawardana, Sameera
    Russo, Francesca
    Walgren, Richard A.
    Zimmermann, Annamaria H.
    Hozak, Rebecca R.
    Bell-McGuinn, Katherine M.
    Powles, Thomas
    LANCET ONCOLOGY, 2020, 21 (01): : 105 - 120
  • [7] Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
    Andrea Necchi
    Hiroyuki Nishiyama
    Nobuaki Matsubara
    Jae-Lyun Lee
    Daniel P. Petrylak
    Ronald de Wit
    Alexandra Drakaki
    Astra M. Liepa
    Huzhang Mao
    Katherine Bell-McGuinn
    Thomas Powles
    BMC Urology, 20
  • [8] Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
    Necchi, Andrea
    Nishiyama, Hiroyuki
    Matsubara, Nobuaki
    Lee, Jae-Lyun
    Petrylak, Daniel P.
    de Wit, Ronald
    Drakaki, Alexandra
    Liepa, Astra M.
    Mao, Huzhang
    Bell-McGuinn, Katherine
    Powles, Thomas
    BMC UROLOGY, 2020, 20 (01)
  • [9] RANGE: A randomized, blinded, placebo-controlled phase III study of ramucirumab plus docetaxel in 2nd-line urothelial carcinoma
    Nishiyama, Hiroyuki
    Asou, Hiroya
    Richard, Walgren
    ANNALS OF ONCOLOGY, 2015, 26 : 144 - 144
  • [10] Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study
    Van der Heijden, M.
    Powles, T.
    Petrylak, D.
    de Wit, R.
    Chi, K.
    Necchi, A.
    Sternberg, C. N.
    Matsubara, N.
    Nishiyama, H.
    Castellano, D.
    Hussain, S.
    Bamias, A.
    Hozak, R.
    Rhodes, R.
    Xia, M. S.
    Rasmussen, E.
    Aggarwal, A.
    Wijayawardana, S.
    Bell-McGuinn, K. M.
    Drakaki, A.
    ANNALS OF ONCOLOGY, 2019, 30
12345